Relmada Therapeutics (RLMD) Set to Announce Earnings on Wednesday

Relmada Therapeutics (NASDAQ:RLMD) will be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.90) per share for the quarter.

Relmada Therapeutics (NASDAQ:RLMD) last announced its quarterly earnings data on Tuesday, March 19th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.04. On average, analysts expect Relmada Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relmada Therapeutics Stock Performance

Relmada Therapeutics stock traded up $0.01 during trading on Tuesday, reaching $3.86. The company had a trading volume of 32,576 shares, compared to its average volume of 235,250. Relmada Therapeutics has a 12-month low of $2.36 and a 12-month high of $7.22. The stock’s 50 day moving average price is $4.90 and its two-hundred day moving average price is $4.01. The firm has a market capitalization of $116.46 million, a price-to-earnings ratio of -1.17 and a beta of 0.27.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.